Artiva Biotherapeutics Inc. (ARTV) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ARTV carries an RQD Score of 39 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 3 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. The company reported no revenue in FY 2025 and an FCF of $-79.3M, so the cash-generation pillar is at its floor. For a prospective investor, this means the stock currently offers no internally generated cash return to support valuation; any upside depends on external funding or a future pipeline outcome that the source data does not establish.
• Whale 13F Flow: 9 / 20. The rating labels this pillar as institutional accumulation and options positioning. The source data contains no 13F holder detail (see Analyst View section), so the basis for this score cannot be verified from the provided material. Investors should treat this pillar as lower-confidence than the financial pillars.
• Insider Conviction: 5 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. No insider transactions are itemized in the source data, so the specific drivers of this score are not verifiable here.
• Macro Regime Fit: 15 / 20. The rating cites a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broader market; for a loss-making biotech, that market sensitivity sits alongside company-specific risk that beta does not capture.
• Forensic Balance Sheet: 7 / 20. The rating cites an Altman Z-Score of 1.03, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. A low Altman Z and Piotroski score point to elevated financial distress and weak fundamental quality. Investors should weigh this pillar heavily, since it bears directly on solvency and dilution risk.

Investor implications: The combined rating points to a vulnerable balance sheet and weak cash flow. The sharpest upside driver would be a demonstrated clinical or commercial catalyst that restores investor confidence, but the recent news flow (Section: Recent Catalysts) points in the opposite direction. Valuation tradeoffs are significant: with no reported earnings and a negative ROIC, conventional earnings multiples cannot be computed from the source data.

Artiva Biotherapeutics Inc. (ARTV) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company's market capitalization is $0.2B. The source data does not describe the company's products, customers, or revenue model. Per the Financial Trend data, reported revenue fell from $32.9M in FY 2023 to $0.3M in FY 2024 and $0.0M in FY 2025, but the source data does not explain the sources of that revenue.

Per the SEC financials, the company reported operating losses in each period shown, with net losses of $-83.9M in FY 2025 and $-65.4M in FY 2024. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is -35%. Per the forensic balance sheet inputs in the RQD rating, the Altman Z-Score is 1.03, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash declined from $40.2M in FY 2024 to $26.7M in FY 2025, and the source data does not provide FY 2023 cash or any period's debt figure.

Per the recent news and catalysts feed, the dominant items are negative:

• Risk Watch (RED): A Stock Titan report states that about 94% of the workforce is being cut as the company ends therapy development.
• Lead asset discontinued: A Seeking Alpha report describes the stock as down after discontinuing its lead asset.
• Trial halted: An Investing.com report describes the stock tumbling after a drug trial was halted.
• Price action: A Benzinga report covers the stock tumbling on the day, and a Yahoo Finance Australia item covers general market action and institutional positioning.
• Analyst coverage: A Simply Wall St item covers stock forecasts and analyst predictions, but the analyst data section contains no usable figures.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as "NONE," with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, no upstream or downstream links, supply-chain dependencies, or proprietary signals are mapped for ARTV. Sector and industry classification (Health Care; Biological Products) are the only structural data available. For a prospective investor, the most relevant second-order watch item is the news flow itself: the workforce reduction and discontinuation of the lead asset imply that the company's operating footprint and pipeline are contracting, which the source data does not quantify. Investors should monitor whether reported cash of $26.7M (FY 2025) is sufficient relative to the FY 2025 FCF of $-79.3M, since the source data does not establish a funding runway.

• What is the company's cash runway given reported cash of $26.7M against FY 2025 FCF of $-79.3M?
• What specific therapy programs were discontinued, and what is the remaining pipeline?
• What is the total debt position, since the source data lists debt as N/A for all periods?
• What drove the revenue decline from $32.9M in FY 2023 to $0.0M in FY 2025?
• What is the basis for the 13F, insider, and congressional flow scores given that no holder or transaction data is provided?